Ann: PAR Selects Advanced Clinical as CRO for Phase 3, page-14

I think it is price sensitive.
The clinical trial runner engagement is accepting a long term cost obligation and laying your money down on the table.

This step is critical to deals IMO as it allows more confidence that P3 is truly underway, shows hard commitment and gives a framework for cost discussions with funding parties.
We also now have a rough idea of when dosing starts and that will inform when early readouts may be expected.

Getting the ball rolling with dosing in AUS ASAP will provide early data for risk mitigation. It also allows protocols to be streamlined prior to US and ROW dosing which will be more expensive per head due to exchange rates and long distance management needs.